[^1]
[^2]
[^3]
[^4]
[^5]
[^6]
[^7]
[^8]
[^9]
[^10]
[^11]
[^12]
[^13]
[^14]
[^15]
[^16]
| Lineage | Neuron > Autophagy-Impaired |
| Markers | p62, LC3-II, LAMP2, Beclin-1, ATG5, ATG7 |
| Brain Regions | Substantia Nigra, Hippocampus, Cerebral Cortex, Cerebellum |
| Disease Relevance | Alzheimer's Disease, Parkinson's Disease, Huntington's Disease, ALS, Batten Disease |
[^17]
Autophagy Impaired Neurons plays an important role in the study of neurodegenerative diseases. This page provides comprehensive information about this topic, including its mechanisms, significance in disease processes, and therapeutic implications.
Autophagy-impaired neurons represent a pathological state characterized by defective autophagic degradation, leading to the accumulation of dysfunctional organelles, protein aggregates, and other cellular debris that would normally be cleared through the autophagy-lysosome pathway [1]. Autophagy (meaning "self-eating") is a critical cellular housekeeping mechanism that maintains neuronal health by removing damaged components, recycling nutrients, and eliminating potentially toxic protein aggregates [2]. When autophagy fails, neurons become vulnerable to proteotoxic stress, mitochondrial dysfunction, and eventual cell death [3].
Unlike most other cell types, neurons are particularly dependent on autophagy due to their post-mitotic nature. Without the ability to divide and dilute accumulated damage, neurons rely heavily on autophagy to maintain cellular homeostasis throughout the lifespan [4]. This makes autophagy impairment particularly devastating for neuronal function and survival.
- mTORC1 hyperactivation: Inhibits ULK1 complex formation [5]
- AMPK dysfunction: Fails to activate autophagy during stress [6]
- ULK1/2 mutations: Impaired initiation complex [7]
- Beclin-1 deficiency: Reduced autophagosome nucleation [8]
- ATG proteins deficiency: Failed conjugation systems [9]
- LC3 lipidation defects: Impaired membrane recruitment [10]
- ATG5/ATG7 mutations: Blocked autophagosome formation [11]
- ATG16L1 dysfunction: Failed ATG5-ATG12 complex [12]
- Cathepsin deficiency: Impaired protein degradation [13]
- LAMP2 mutations: Danon disease with neurodegeneration [14]
- V-ATPase impairment: Failed acidification [15]
- Lysosomal storage diseases: Accumulation of undegraded material [16]
¶ Cargo Recognition and Delivery
- p62/SQSTM1 dysfunction: Failed selective autophagy [17]
- NBR1 deficiency: Impaired aggregate clearance [18]
- OPTN mutations: Defective mitophagy [19]
- Tollip dysfunction: Impaired innate immunity autophagy [20]
- Autophagosome formation defects: Impaired initiation and elongation [21]
- Cargo recognition failures: Selective autophagy impairments [22]
- Fusion障碍: Autophagosome-lysosome fusion problems [23]
- Lysosomal degradation defects: Final step failure [24]
- PINK1/Parkin pathway dysfunction: Failed mitochondrial quality control [25]
- OPTN deficiency: Impaired receptor-mediated mitophagy [26]
- FUNDC1 mutations: Hypoxia-induced mitophagy defects [27]
- BNIP3/NIX dysfunction: Alternative mitophagy pathway [28]
- LAMP-2A deficiency: Impaired CMA receptor function [29]
- HSC70 dysfunction: Failed substrate recognition [30]
- CMA substrate accumulation: Specific protein accumulation [31]
¶ Ribophagy and ER-Phagy
- Ribophagy defects: Impaired ribosomal turnover [32]
- ER-phagy receptor dysfunction: Failed ER clearance [33]
- Ubiquitin-positive inclusions: Accumulated misfolded proteins
- Autophagic vacuole accumulation: Failed degradation [35]
- Aggresome formation: Microtubule-dependent inclusions [36]
- Impaired proteostasis: Global protein quality control failure [37]
- Damaged mitochondria accumulation: Failed mitophagy
- Energy deficit: Reduced ATP production
- ROS overproduction: Oxidative stress accumulation
- Calcium buffering impairment: Dysregulated calcium
- Lipofuscin accumulation: Age-related pigment [42]
- Ceroid accumulation: Lysosomal storage [43]
- Lysosomal membrane permeabilization: Cell death activation [44]
- **Autoimmune lysosomal dysfunction: Disease-specific patterns [45]
- Autophagic vacuoles in AD: Characteristic pathology [46]
- Beclin-1 reduction: Impaired autophagosome formation [47]
- mTOR hyperactivation: Inhibited autophagy initiation [48]
- Lysosomal dysfunction: Cathepsin deficiency [49]
¶ Amyloid and Tau Effects
- Aβ-induced autophagy defects: Toxic oligomer effects [50]
- Tau-mediated autophagy impairment: Phosphorylated tau [51]
- Presenilin mutations: Impaired lysosomal acidification [52]
- mTOR inhibitors: Rapamycin enhances autophagy [53]
- Lithium: Autophagy induction [54]
- Carbamazepine: TFEB activation [55]
- PINK1 mutations: Impaired mitophagy initiation [56]
- Parkin mutations: Failed substrate recognition [57]
- DJ-1 deficiency: Impaired mitophagy regulation [58]
- Complex I deficiency: Mitochondrial damage accumulation [59]
- Impaired autophagic degradation: Aggregate accumulation [60]
- p62 dysfunction: Failed selective autophagy [61]
- GCH1 deficiency: Impaired dopamine synthesis [62]
- Urolithin A: Mitophagy induction [63]
- CoQ10: Mitochondrial support [64]
- NAD+ precursors: Sirtuin activation [65]
- Huntingtin sequestration of beclin-1: Impaired autophagy [66]
- Transcriptional dysregulation: Autophagy gene suppression [67]
- Aggregate-mediated inhibition: Autophagic flux blockade [68]
- mTOR inhibition: Rapamycin treatment [69]
- Minocycline: Autophagy enhancement [70]
- Lithium: Autophagy induction [71]
- ALS-associated mutations: Multiple autophagy genes [72]
- SOD1 aggregates: Impaired clearance [73]
- TDP-43 pathology: Autophagic stress [74]
- Arimoclomol: HSP induction [75]
- Rapamycin: Autophagy enhancement [76]
- Trehalose: Autophagy inducer [77]
- Rapamycin/sirolimus: mTORC1 inhibition [78]
- Lithium: GSK3β inhibition and autophagy [79]
- Carbamazepine: ER stress and autophagy [80]
- Metformin: AMPK activation [81]
- Resveratrol: SIRT1 activation [82]
- Curcumin: Autophagy modulation [83]
- Sulforaphane: Nrf2-mediated autophagy [84]
- Trehalose: mTOR-independent autophagy [85]
- ATG gene delivery: Restore missing components [86]
- Beclin-1 overexpression: Enhance initiation [87]
- TFEB activation: Lysosomal biogenesis [88]
- 3-MA treatment: Pharmacological inhibition [89]
- BafA1 treatment: Lysosomal blockade [90]
- ATG knockout neurons: Genetic models [91]
- Patient iPSC neurons: Disease-specific defects [92]